International Clinics
Daily
FDA approves tucatinib as chemotherapy-free maintenance for advanced HER2-positive breast cancer
On 7 October 2026 the FDA approved Tukysa (tucatinib) with trastuzumab and pertuzumab as maintenance for advanced HER2-positive breast cancer.
